Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.

@article{Ohman1997CombinedAT,
  title={Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.},
  author={E Magnus Ohman and Neal S. Kleiman and Gerald M. Gacioch and Seth Joseph Worley and F I Navetta and J. David Talley and H. Vernon Anderson and Stephen G. Ellis and Mark D. Cohen and Douglas Spriggs and Michael Miller and Dean J Kereiakes and Steven L Yakubov and Michael M. Kitt and Kristina N. Sigmon and Robert M. Califf and Mitch W Krucoff and Eric J. Topol},
  journal={Circulation},
  year={1997},
  volume={95 4},
  pages={846-54}
}
BACKGROUND Platelet activation and aggregation may be key components of thrombolytic failure to restore and maintain perfusion in acute myocardial infarction. We performed a placebo-controlled, dose-ranging trial of Integrilin, a potent inhibitor of platelet aggregation, with heparin, aspirin, and accelerated alteplase. METHODS AND RESULTS We assigned 132 patients in a 2:1 ratio to receive a bolus and continuous infusion of one of six Integrilin doses or placebo. Another 48 patients were… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 105 extracted citations

Similar Papers

Loading similar papers…